Gonadotropin-releasing hormone functionally antagonizes testosterone activation of the human androgen receptor in prostate cells through focal adhesion complexes involving Hic-5

Neuroendocrinology

Volumn 84, Issue 5, 2007, Pages 285-300

  Maudsley, Stuart ^a   Davidson, Lindsay ^a   Pawson, Adam J ^a   Freestone, Sarah H ^a   López De Maturana, Rakel ^b   Thomson, Axel A ^a   Millar, Robert P ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b Ardana   (France)

Author keywords

Androgen receptor; Calcium dependent tyrosine kinase, Pyk2; Gonadotropin releasing hormone; Hydrogen peroxide inducible clone 5 protein, Hic 5; Non receptor tyrosine kinase, c Src; Prostatic cancer; Testosterone

Indexed keywords

ANDROGEN RECEPTOR; FOCAL ADHESION KINASE 2; GONADORELIN; GONADORELIN RECEPTOR; GREEN FLUORESCENT PROTEIN; HYDROGEN PEROXIDE INDUCIBLE CLONE 5 PROTEIN; PROTEIN; PROTEIN TYROSINE KINASE; TESTOSTERONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG MECHANISM; EMBRYO; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MALE; NONHUMAN; ORGAN CULTURE; PRIORITY JOURNAL; PROSTATE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; TISSUE GROWTH;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANIMALS, NEWBORN; CELL NUCLEUS; CELLS, CULTURED; FOCAL ADHESION PROTEIN-TYROSINE KINASES; FOCAL ADHESIONS; GONADOTROPIN-RELEASING HORMONE; GREEN FLUORESCENT PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PROSTATE; PROTEIN-TYROSINE KINASES; RATS; RATS, WISTAR; RECEPTORS, ANDROGEN; TESTOSTERONE; TRANS-ACTIVATION (GENETICS);

EID: 33947152165     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098402     Document Type: Article

References (56)

1. Conn PM, Crowley WF, Jr: Gonadotropin-releasing hormone and its analogs. Annu Rev Med 1994;45:391-405.
2. Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, Maudsley S: Gonadotropin-releasing hormone receptors. Endocr Rev 2004;25:235-275.
3. Naor Z, Benard O, Seger R: Activation of MAPK cascades by G-protein-coupled receptors: the case of gonadotropin-releasing hormone receptor. Trends Endocrinol Metab 2000;11:91-99.
4. Conn PJ, Pin JP: Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997;37:205-237.
5. Limonta P, Montagnani Marelli M, Moretti RM: LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drugs 2001;10:709-720.
6. Maria Comaru-Schally A, Schally AV: Rational use of agonists and antagonists of luteinizing hormone-releasing hormone in the treatment of hormone-sensitive neoplasms and gynaecologic conditions. Adv Drug Deliv Rev 1997;28:157-169.
7. Klijn JG, de Jong FH: Treatment with a luteinising-hormone-releasing- hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer. Lancet 1982;i:1213-1216.
8. Eidne KA, Flanagan CA, Millar RP: Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science 1985;229:989-991.
9. Miller WR, Scott WN, Morris R, Fraser HM, Sharpe RM: Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 1985;313:231-233.
10. Eidne KA, Flanagan CA, Harris NS, Millar RP: Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J Clin Endocrinol Metab 1987;64:425-432.
11. Emons G, Schally AV: The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum Reprod 1994;9:1364-1379.
12. Limonta P, Moretti RM, Marelli MM, Motta M: The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans. Front Neuroendocrinol 2003;24:279-295.
13. Limonta P, Moretti RM, Marelli MM, Dondi D, Parenti M, Motta M: The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway. Endocrinology 1999;140:5250-5256.
14. Limonta P, Dondi D, Moretti RM, Fermo D, Garattini E, Motta M: Expression of luteinizing hormone-releasing hormone mRNA in the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 1993;76:797-800.
15. Straub B, Muller M, Krause H, Schrader M, Goessl C, Heicappell R, Miller K: Increased incidence of luteinizing hormone-releasing hormone receptor gene messenger RNA expression in hormone-refractory human prostate cancers. Clin Cancer Res 2001;7:2340-2343.
16. Limonta P, Dondi D, Moretti RM, Maggi R, Motta M: Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 1992;75:207-212.
17. Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E, Motta M: Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Cancer Res 1994;54:4091-4095.
18. Dondi D, Moretti RM, Montagnani Marelli M, Pratesi G, Polizzi D, Milani M, Motta M, Limonta P: Growth-inhibitory effects of luteinizing hormone-releasing hormone agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice. Int J Cancer 1998;76:506-511.
19. Jungwirth A, Galvan G, Pinski J, Halmos G, Szepeshazi K, Cai RZ, Groot K, Schally AV: Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate 1997;32:164-172.
20. Moretti RM, Marelli MM, Dondi D, Poletti A, Martini L, Motta M, Limonta P: Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. J Clin Endocrinol Metab 1996;81:3930-3937.
21. Franklin J, Hislop J, Flynn A, McArdle CA: Signalling and anti-proliferative effects mediated by gonadotrophin-releasing hormone receptors after expression in prostate cancer cells using recombinant adenovirus. J Endocrinol 2003;176:275-284.
22. Imai A, Horibe S, Takagi H, Fuseya T, Tamaya T: Signal transduction of GnRH receptor in the reproductive tract tumor. Endocr J 1996;43:249-260.
23. αi -coupling state of the type I GnRH receptor. Cancer Res 2004;64:7533-7544.
24. 2 -terminal kinase, protein kinase B, and extracellular signal-regulated kinase pathways. Cancer Res 2004;64:5736-5744.
25. Demay F, De Monti M, Tiffoche C, Vaillant C, Thieulant ML: Steroid-independent activation of ER by GnRH in gonadotrope pituitary cells. Endocrinology 2001;142:3340-3347.
26. Turgeon JL, Waring DW: Activation of the progesterone receptor by the gonadotropin-releasing hormone self-priming signaling pathway. Mol Endocrinol 1994;8:860-869.
27. Fujimoto N, Yeh S, Kang HY, Inui S, Chang HC, Mizokami A, Chang C: Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem 1999;274:8316-8321.
28. Fujimoto N, Mizokami A, Harada S, Matsumoto T: Different expression of androgen receptor coactivators in human prostate. Urology 2001;58:289-294.
29. Matsuya M, Sasaki H, Aoto H, Mitaka T, Nagura K, Ohba T, Ishino M, Takahashi S, Suzuki R, Sasaki T: Cell adhesion kinase beta forms a complex with a new member, Hic-5, of proteins localized at focal adhesions. J Biol Chem 1998;273:1003-1014.
30. 3- dependent tyrosine phosphorylation and association with proline-rich tyrosine kinase 2. Biochem J 2001;355:691-697.
31. Ishino M, Aoto H, Sasaski H, Suzuki R, Sasaki T: Phosphorylation of Hic-5 at tyrosine 60 by CAKβ and Fyn. FEBS Lett 2000;474:179-183.
32. Nishiya N, Iwabuchi Y, Shibanuma M, Cote JF, Tremblay ML, Nose K: Hic-5, a paxillin homologue, binds to the protein-tyrosine phosphatase PEST (PTP-PEST) through its LIM 3 domain. J Biol Chem 1999;274:9847-9853.
33. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM: Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998;280:1614-1617.
34. Shibanuma M, Mochizuki E, Maniwa R, Mashimo J, Nishiya N, Imai S, Takano T, Oshimura M, Nose K: Induction of senescence-like phenotypes by forced expression of hic-5, which encodes a novel LIM motif protein, in immortalized human fibroblasts. Mol Cell Biol 1997;17:1224-1235.
35. Shibanuma M, Nose K: Forced expression of hic-5, a senescence-related gene, potentiates a differentiation process of RCT-1 cells induced by retinoic acid. Int J Biochem Cell Biol 1998;30:39-45.
36. Stanzione R, Picascia A, Chieffi P, Imbimbo C, Palmieri A, Mirone V, Staibano S, Franco R, De Rosa G, Schlessinger J, Tramontano D: Variations of proline-rich kinase Pyk2 expression correlate with prostate cancer progression. Lab Invest 2001;81:51-59.
37. Maudsley S, Millar RP, Brown P: Selective ERK activation of a novel early growth response-1 DNA element via a focal adhesion based mechanism by gonadotropin-releasing hormone. 83rd Annual Meeting of The Endocrine Society, Denver 2001, P3-P278.
38. Davidson L, Pawson AJ, Millar RP, Maudsley S: Cytoskeletal reorganization dependence of signaling by the gonadotropin-releasing hormone receptor. J Biol Chem 2004;279:1980-1993.
39. Millar RP, Lowe S, Conklin D, Pawson A, Maudsley S, Troskie B, Ott T, Millar M, Lincoln G, Sellar R, Faurholm B, Scobie G, Kuestner R, Terasawa E, Katz A: A novel mammalian receptor for the evolutionarily conserved type II GnRH. Proc Natl Acad Sci USA 2001;98:9636-9641.
40. Thomson AA, Cunha GR: Prostatic growth and development are regulated by FGF10. Development 1999;126:3693-3701.
41. Wang X, Yang Y, Guo X, Sampson ER, Hsu CL, Tsai MY, Yeh S, Wu G, Guo Y, Chang C: Suppression of androgen receptor transactivation by Pyk2 via interaction and phosphorylation of the ARA55 coregulator. J Biol Chem 2002;277:15426-15431.
42. Luttrell LM, Daaka Y, Lefkowitz RJ: Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Curr Opin Cell Biol 1999;11:177-183.
43. Thomas SM, Hagel M, Turner CE: Characterization of a focal adhesion protein, Hic-5, that shares extensive homology with paxillin. J Cell Sci 1999;112:181-190.
44. Kaplan KB, Bibbins KB, Swedlow JR, Arnaud M, Morgan DO, Varmus HE: Association of the amino-terminal half of c-Src with focal adhesions alters their properties and is regulated by phosphorylation of tyrosine 527. EMBO J 1994;13:4745-4756.
45. Birge RB, Fajardo JE, Reichman C, Shoelson SE, Songyang Z, Cantley LC, Hanafusa H: Identification and characterization of a high-affinity interaction between v-Crk and tyrosine-phosphorylated paxillin in CT10-transformed fibroblasts. Mol Cell Biol 1993;13:4648-4656.
46. Sabe H, Hata A, Okada M, Nakagawa H, Hanafusa H: Analysis of the binding of the Src homology 2 domain of Csk to tyrosine-phosphorylated proteins in the suppression and mitotic activation of c-Src. Proc Natl Acad Sci USA 1994;91:3984-3988.
47. Schaller MD, Parsons JT: pp125FAK-dependent tyrosine phosphorylation of paxillin creates a high-affinity binding site for Crk. Mol Cell Biol 1995;15:2635-2645.
48. 1-inducible hic-5 gene that encodes a putative novel zinc finger protein and its possible involvement in cellular senescence. J Biol Chem 1994;269:26767-26774.
49. Glenney JR, Jr, Zokas L: Novel tyrosine kinase substrates from Rous sarcoma virustransformed cells are present in the membrane skeleton. J Cell Biol 1989;108:2401-2408.
50. Salgia R, Brunkhorst B, Pisick E, Li JL, Lo SH, Chen LB, Griffin JD: Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene 1995;11:1149-1155.
51. Yang L, Guerrero J, Hong H, DeFranco DB, Stallcup MR: Interaction of the τ2 transcriptional activation domain of glucocorticoid receptor with a novel steroid receptor coactivator, Hic-5, which localizes to both focal adhesions and the nuclear matrix. Mol Biol Cell 2000;11:2007-2018.
52. Lee DK, Chang C: Molecular communication between androgen receptor and general transcription machinery. J Steroid Biochem Mol Biol 2003;84:41-49.
53. Fu M, Rao M, Wu K, Wang C, Zhang X, Hessien M, Yeung YG, Gioeli D, Weber MJ, Pestell RG: The androgen receptor acetylation site regulates cAMP and AKT but not ERKinduced activity. J Biol Chem 2004;279:29436-29449.
54. Zhou ZX, Kemppainen JA, Wilson EM: Identification of three proline-directed phosphorylation sites in the human androgen receptor. Mol Endocrinol 1995;9:605-615.
55. Gnanapragasam VJ, Darby S, Khan MM, Lock WG, Robson CN, Leung HY: Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer. J Pathol 2005;206:205-213.
56. Millar RP, Pawson AJ: Outside-in and inside-out signaling: the new concept that selectivity of ligand binding at the gonadotropin-releasing hormone receptor is modulated by the intracellular environment. Endocrinology 2004;145:3590-3593.